Serum cholinesterase combined with platelet-to-hemoglobin ratio for predicting survival prognosis in stage I-III colorectal cancer patients undergoing radical surgery: a retrospective cohort study.

ABSTRACT:

Background

Although surgery-based comprehensive therapy is highly effective for treating stage I-III colorectal cancer, heterogeneity in survival trajectories still exists, necessitating precise prognostic stratification. Serum cholinesterase (CHE) and the platelet-to-hemoglobin ratio (PHR) are emerging as potential prognostic markers reflecting inflammation, nutritional status, and tumor biology. This study aims to investigate their combined value in predicting survival outcomes for stage I-III CRC patients, potentially offering a cost-effective tool for personalized management.

Methods

The study included 673 stage I-III CRC patients who underwent radical surgery at Harbin Medical University Cancer Hospital from January to August 2019 and January to March 2020. Comprehensiv

SUBMITTER: Huang L 

PROVIDER: S-EPMC12042540 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature